Microbot Medical receives non-dilutive grant of NIS 2.15M from IIA

Microbot Medical (MBOT) announced it has been approved to receive a non-dilutive grant from the Israel Innovation Authority, IIA, in the amount of NIS 2.15 Million. The funding will further strengthen the Company’s manufacturing capabilities, positioning it to successfully implement the commercialization of the LIBERTY System, pending marketing clearance by the U.S. Food and Drug Administration, FDA. In addition to recognizing the Company’s recent milestone achievements, the IIA acknowledged several other factors in its final decision, including the size and characteristics of the target market, the competitive advantages of a single-use, disposable robot, the regulatory status of the LIBERTY System and the overall benefits it is expected to deliver to the end user and healthcare system. The Company believes that the grant validates its technology and reflects the rigorous, independent due diligence conducted by the IIA.